>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

Summary

7.98 0.02 (0.25%) 09/16/2026
SOPHiA GENETICS S.A. (SOPH)
Performance
Historical returns
1D
0.25%
1W
3.65%
1M
4.33%
3M
58.88%
6M
62.12%
1Y
151.10%
5Y
-50.96%
Snapshot
Key statistics
Close
7.98
Change
0.02
Change %
0.25%
Open
7.98
Day Range
7.83 – 8.10
Volume
1,490,306
Avg Vol (20d)
638,605
Rel Vol
2.33x
52W Range
3.15 - 8.98
vs 52W High
-11.14%
vs 52W Low
153.33%
Gap
-0.15
Market Cap
USD 669.06M
Beta
1.11
Price Chart
Advanced chartCompare
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Bull vs Bear
8 bullish · 4 bearish points
Bullish view
  • Operating margin expanded to -86.0% in the Jun 2026 quarter from -101.3% a year earlier.
  • Revenue grew 27.2% year on year in the Jun 2026 quarter to $23.31M.
  • FY2025 earnings rose 28.9% to -$79.00M.
  • Consensus has EPS compounding 5,200.0% a year to $0.53 by 2030, which grows the multiple down to 15.1×.
  • Sits 25.3% below the average analyst target of $10.00 across 3 firms.
  • Revenue in the same quarter came in $1.59M ahead of consensus.
  • Holds 45.2% above its 200-day average.
  • Has recovered 150.2% off the 52-week low of $3.19.
Bearish view
  • Gross margin slipped to 64.6% from 67.0% a year ago.
  • Trades at 798× the 2029 consensus EPS of $0.01, a multiple that leaves little room for disappointment.
  • Missed consensus EPS in 6 of the last 8 quarters.
  • The Q2 '26 quarter missed on EPS by $0.05 (23.8% below consensus).
Both sides are generated from reported financials, consensus estimates, analyst targets and the price series — not from opinion.
Notable Price Movement
Historical returns
Sep 16
2026
$7.98 0.25%Latest
SOPHiA GENETICS rose 0.25% to $7.98, on 2.3× average volume. The move left the stock 10.5% below its 52-week high.
Sep 9
2026
$7.68 8.13%
SOPHiA GENETICS fell 8.13% to $7.68, a 1.7σ move against its 60-day volatility, on 1.5× average volume. This was largely stock-specific: the S&P 500 fell 0.46% while Healthcare peers (XLV) fell 0.33% that session, leaving about 7.6 points of the move unexplained by the market after adjusting for a 1.11 beta. Shares closed near the session low (5% of the day's range) and lost their 20-day moving average.
Aug 28
2026
$8.14 8.74%
SOPHiA GENETICS fell 8.74% to $8.14, its biggest one-day drop in 6 months and a 1.9σ move against its 60-day volatility. This was largely stock-specific: the S&P 500 fell 0.23% while Healthcare peers (XLV) fell 0.24% that session, leaving about 8.5 points of the move unexplained by the market after adjusting for a 1.11 beta. Shares opened with a 1.35% gap down and closed near the session low (9% of the day's range).
Aug 27
2026
$8.92 4.57%52W High
SOPHiA GENETICS rose 4.57% to $8.92. This was largely stock-specific: the S&P 500 gained 0.66% while Healthcare peers (XLV) fell 1.13% that session, leaving about 3.8 points of the move unexplained by the market after adjusting for a 1.11 beta. Shares closed near the session high (89% of the day's range) and set a 52-week closing high.
Aug 21
2026
$8.65 3.84%52W High
SOPHiA GENETICS rose 3.84% to $8.65. Roughly 2.5 points were stock-specific — the S&P 500 gained 0.41% while Healthcare peers (XLV) rose 1.29% alongside it. Shares closed near the session high (92% of the day's range), set a 52-week closing high and marked a 3rd consecutive advance.
Aug 19
2026
$8.28 8.66%52W High
SOPHiA GENETICS rose 8.66% to $8.28, a 1.9σ move against its 60-day volatility, on 3.2× average volume. Roughly 5.2 points were stock-specific — the S&P 500 gained 0.21% while Healthcare peers (XLV) rose 3.51% alongside it. Shares opened with a 1.44% gap up, closed near the session high (95% of the day's range) and set a 52-week closing high. Historically, after 1.9σ-or-larger up days, SOPHiA GENETICS returned -0.94% on average over the following 5 sessions (47% positive, n=30).
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
Price Performance
All periods
PeriodPeriod LowPeriod HighPerformance
1-Month7.46 +6.97%
on 08/17/26
Open 7.63
8.98 -11.14%
on 08/27/26
+0.35 (+4.59%)
since 08/17/26
3-Month4.84 +64.88%
on 06/16/26
Open 4.93
8.98 -11.14%
on 08/27/26
+3.05 (+61.87%)
since 06/16/26
6-Month4.44 +79.73%
on 05/18/26
Open 5.00
8.98 -11.14%
on 08/27/26
+2.98 (+59.60%)
since 03/17/26
YTD4.01 +99.00%
on 03/03/26
Open 4.67
8.98 -11.14%
on 08/27/26
+3.31 (+70.88%)
since 01/02/26
52-Week3.12 +155.77%
on 09/15/25
Open 3.17
8.98 -11.14%
on 08/27/26
+4.81 (+151.74%)
since 09/15/25
5-Year1.69 +373.59%
on 11/09/22
Open 17.76
19.19 -58.42%
on 10/01/21
-9.78 (-55.07%)
since 09/08/21
New Highs
Historical highs
5-Day
3×
0.00% from peak
1-Month
4×
-10.54% from peak
3-Month
13×
-10.54% from peak
6-Month
18×
-10.54% from peak
YTD
16×
-10.54% from peak
52-Week
21×
-10.54% from peak
2-Year
19×
-10.54% from peak
3-Year
41×
-10.54% from peak
5-Year
4×
-57.55% from peak
10-Year
n/a
not enough history
Financial SnapshotFY 2025
Full financials
Revenue
USD 77.27M
+18.6% YoY
Net Income
-USD 79.00M
+28.9% YoY
EPS
-1.17
+23.2% YoY
Gross Margin
61.9%
Operating Margin
-91.8%
Net Margin
-102.2%
EBITDA
-USD 64.40M
Free Cash Flow
-USD 38.59M
-49.9% margin
ROE
-167.6%
ROA
-48.3%
Debt / Equity
1.34x
net debt -USD 7.27M
Cash & Equiv.
USD 70.29M
News
All news
08/27 08:35 ET · marketbeat.com
When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals
The volume of shares traded in a session often gets a passing mention in the financial press until a stock experiences unusually high volume. That's because volume can provide an important measure of the conviction behind a stock's price movement.
08/25 03:47 ET · defenseworld.net
SOPHiA GENETICS (NASDAQ:SOPH) Sets New 1-Year High – What’s Next?
SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) reached a new 52-week high during trading on Tuesday. The stock traded as high as $8.84 and last traded at $8.45, with a volume of 655541 shares trading hands. The stock had previously closed at $8.65. Analyst Ratings Changes SOPH has been the...
08/04 17:10 ET · seekingalpha.com
SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript
08/04 14:06 ET · marketbeat.com
SOPHiA GENETICS Q2 Earnings Call Highlights
SOPHiA GENETICS NASDAQ: SOPH reported second-quarter revenue growth of 27% and raised its full-year revenue outlook, as the precision medicine software company cited accelerating U.S. adoption, liquid biopsy momentum and new biopharma agreements.
08/04 06:45 ET · prnewswire.com
SOPHiA GENETICS Reports Second Quarter 2026 Results
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Revenue was $23.3 million, up 27%...
08/04 06:15 ET · prnewswire.com
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN). This multi-year...
07/21 08:00 ET · prnewswire.com
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
BOSTON and ROLLE, Switzerland, July 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced it will release its financial results for the second quarter 2026 before U.S. markets open on Tuesday, August 4, 2026. On that day, SOPHiA...
06/22 08:25 ET · prnewswire.com
SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting
Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of his appointment as CEO effective July 1, 2026 ROLLE, Switzerland, June 22, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global...

Market News ×
Loading news…